# Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis

> **NCT05553236** · NA · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 2500 (estimated)

## Conditions studied

- Drug-resistant Tuberculosis
- HIV Coinfection
- Cost-Benefit Analysis

## Interventions

- **DIAGNOSTIC_TEST:** Targeted next-generation sequencing

## Key facts

- **NCT ID:** NCT05553236
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 2500 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05553236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05553236, "Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05553236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*